Evidence map›Paper›PMID 35802835›Full record

ArticleJCO global oncology2022

Impact of the First Wave of COVID-19 Pandemic on Radiotherapy Practice at Tata Memorial Centre, Mumbai: A Longitudinal Cohort Study.

Anil Tibdewal, Rima Pathak, Anuj Kumar, Sachith Anand, Sarbani Ghosh Laskar, Rajiv Sarin, Supriya Chopra, Reena Engineer, Siddharth Laskar, Vedang Murthy and 2 more

Open access · goldAbstract read
In one paragraph

Article in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Nursing Care for Metastatic Bone Cancer: Trends for the Future.International journal of environmental research and public health · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Anil TibdewalDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-0374-0800
Rima PathakDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-4887-7130
Anuj KumarDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0001-9660-1510
Sachith AnandDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Sarbani Ghosh LaskarDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0003-0744-4838
Rajiv SarinDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-6405-8282
Supriya ChopraDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-2656-1792
Reena EngineerDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-3893-1287
Siddharth LaskarDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0001-8558-4225
Vedang MurthyDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0001-6011-9319
Tejpal GuptaDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0001-8256-9206
Jai Prakash AgarwalDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0003-0430-8558
Homi Bhabha National Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDelivery of cancer care during the pandemic required adopting various changes in the standard management. We analyzed the impact of the first wave of the COVID-19 pandemic on radiation oncology treatment practices at Tata Memorial Hospital in India. MATERIALS AND

methodsFrom March 1 to October 31, 2020, all consecutive patients who attended the radiation oncology department for radiotherapy treatment were included in this study. Electronic medical records, patient files, and telephonic consult were used to collect patient's data including changes in the standard treatment practice, COVID-19 testing and its results, and subsequent impact on radiotherapy treatment. Comparison was done with the same period data of 2019 for the number of the caseload, radiotherapy regimen, referral rates, and noncompliance rates.

resultsOur study included 4,256 patients with a median age of 52 years (interquartile range 41-61 years). There was a significant drop in the new-patient registrations (approximately 63%), radiotherapy consultations (44.9%), and referrals to other centers (27.8%). The reduction in the caseload was highest for genitourinary cases (-58.5%) and the lowest for breast cases (-11.5%) when compared with the 2019 cohort. Among those treated with radical intent, the noncompliance rate was 15%. Hypofractionation was the commonly adopted regimen across all sites. Compared with 2019, the maximum reduction in the average fractions per patient was seen in the breast cancer cases (-8.2 fraction), followed by genitourinary cases (-4.9 fraction). Of the 27.8% of patients tested for COVID-19, 13.4% turned positive and 3.4% died due to the disease.

conclusionThe COVID-19 pandemic adversely affected the number of radiotherapy consultations and treatments at our institute. However, our department offered uninterrupted services despite grave challenges. Hypofractionated regimen was used across disease sites to minimize patient visits and allow planned treatment completion. Radiotherapy was delivered safely, and patients experienced low rates of COVID positivity during radiotherapy and even lower mortality.

Indexed as

COVID-19Radiation OncologyAdultCOVID-19 TestingHumansLongitudinal StudiesMiddle AgedPandemics

Identifiers

PMID35802835
PMCPMC9296187
OpenAlexW4284971169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.